Topics Covered
- Phosphoinositide 3-kinase (PI3K) signaling
- Class Ia PI3K's and the mediation of growth factor signaling
- The receptor tyrosine kinase signaling pathway
- Loss-of-function mutations in tumor suppressors
- Sporadic mutations
- Drug targets
- Regulation of metabolism by PI3K AKT signaling
- Targets of the drug NVP BEZ235
- Generation of mice with mutant PI3K p110a
- How lung adenocarcinoma requires mutant PI3K
- HIF-1alpha
- Visualizing lung tumors using FDG PET
- How mTOR inhibition does not reduce tumor volume
- Will a PI3K inhibitor kill K-Ras driven tumors?
- How AKT inhibition does not affect tumor size or activity
- Effects of BEZ235 in K-Ras mutant tumors
- How BEZ235 specifically kills PI3K driven tumors
- The drug ARRY 886
- How PI3K with MEK inhibitors eradicates K-Ras tumors
- Blocking the PI3K and MAP Kinase pathways
- Inhibition of S6 kinase in K-Ras tumors
Links
Series:
Categories:
Talk Citation
Cantley, L. (2010, November 30). Role of the PI 3-kinase signaling pathway in cell regulation and human disease [Video file]. In
The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 10, 2023, from
https://hstalks.com/bs/1880/.
Export Citation (RIS)
Publication History
-
Published on November 30, 2010
Financial Disclosures
- Prof. Lew Cantley, Consultant: Novartis.